A previous study has demonstrated that overexpression of PIM1 is correlated with poor clinical outcomes of DLBCL patients.33 Functionally, PIM1 contributes to cell proliferation in vitro and tumour growth in vivo, indicating a potential therapeutic target in DLBCL.33, 43 Interestingly, SNHG16 overexpression rescued miR‐497‐5p‐induced repression of PIM1. Here, PIM1 is linked to diffuse large B-cell lymphoma.